2021年3月23日/医麦客新闻 eMedClub News/--2021年3月22日，上海吉凯基因医学科技股份有限公司（以下简称“吉凯基因”）与普米斯生物技术（珠海）有限公司（以下简称“普米斯”）共同宣布，双方就两个针对实体瘤的单克隆抗体项目达成全球权益买断交易。这两个单克隆抗体项目最初由吉凯基因和普米斯共同开发，通过此次合作，普米斯将获得这两个项目的全球开发权利，未来将在这两个项目基础上继续开发面向全球市场的多特异性抗体；同时吉凯基因保留将这两个单克隆抗体用于CAR-T细胞疗法的权利。
对于此次合作，普米斯首席执行官刘晓林先生表示：“我们很高兴与吉凯基因建立合作。吉凯基因在细胞疗法和转化科学方面拥有丰富经验，我们在治疗性抗体研发方面拥有多个具有自主知识产权的关键技术平台，相信我们的合作将产生巨大的协同作用，促进我们双方共同快速发展。”
吉凯基因创始人兼总裁曹跃琼女士表示：“利用吉凯基因丰富的临床资源开发针对中国高发癌种的创新药物，对我们而言具有重大的战略意义。要想开发出更多新颖、有效的抗体药物，这需要优秀企业之间的共同合作，普米斯在抗体开发方面的丰富经验与吉凯基因的战略高度契合。”
普米斯
普米斯成立于2018年，始终秉承“点亮创新火种，成就健康人生”的创业使命，聚焦恶性肿瘤及自身免疫疾病，致力于国家一类创新生物药的研发及产业化，现已有多个产品处于临床研究阶段。普米斯成立至今，已经完成四轮融资，同时与珠海高新区政府签订合作协议，得到多项政策扶持。普米斯凭借其高价值的产品链、强大的创新能力、巨大的发展潜力先后被评为“珠海市独角兽潜力企业”、“2019年中国哪吒企业”、“第三届粤港澳大湾区生物科技创新企业50强之领军企业”。
吉凯基因
吉凯基因成立于2002年，是一家以标准化科研大数据为驱动力、以持续开发创新靶点药物为路径、以提高中国高发少药疾病患者生存率和生活质量为使命的平台型公司。生物医学基础研究、生物标志物及药靶发现、新药开发的全产业链发展模式，工程化GRP科研平台，以及干湿结合的研发策略打造了独树一帜的靶标持续发现潜力，合作伙伴覆盖全国300余家研究型医院。已建成高效的抗体药物开发平台和细胞治疗药物开发平台。数个创新药物分子已经实现和制药企业的授权交易。已承担国家地方研发项目30余项，申请发明专利100余项。是上海市专利工作示范企业，上海市科技小巨人企业、高新技术企业。获批建立上海肿瘤药物基因靶标工程技术研究中心、上海市首批十家之一的上海市基因治疗技术创新中心。
Shanghai Genchem Co., Ltd. (Genechem) and Biotheus Announces Acquisition of two Monoclonal Antibodies against Solid Tumors
March 22, 2021, Shanghai Genechem and Biotheus announced a global deal where Biotheus acquired global rights to two monoclonal antibody programs targeting solid tumors, both of which were previously under co-development between the two parties. Biotheus will develop multi-specific antibodies for these programs aimed at commercialization for the global market. Genechem retains rights for using the two antibodies in CAR-T cell therapies.
“We are glad to collaborate with Genechem. Genechem’s extensive experience in cell therapy and translational science, and Biotheus’ extensive experience in therapeutic antibody R&D, has brought great synergy between both parties.” Commented Xiaolin Liu, CEO of Biotheus.
“Development of innovative medicine against prevalent cancers in China, leveraging Genechem’s advantages in the clinical development, is of strategic priority for us. It takes collaborations between outstanding enterprises to develop more novel, effective antibody drugs. Biotheus’ rich experience in antibody development is highly synergistic with ours”. Yueqiong Cao, Founder and CEO of Genechem remarked.
Founded in 2018, Biotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class innovative biologics mainly through the discovery of next-generation multispecific antibodies with multiple programs in the clinical trials. Biotheus has completed four rounds of financing. In addition, Biotheus has received support from the Zhuhai government through a number of initiatives and policies that drive local innovation.
Shanghai Genchem Co., Ltd. (Genechem)
Genechem is a leading innovation and translational research company focused on target discovery/validation, development of antibody and cell therapy products against novel targets, and partnership globally to maximize its portfolio. Founded in 2002 with over 500 employees, Genechem works closely with Clinical Oncologists to translate clinical research into therapeutics addressing high clinical unmet needs, leveraging its strong network of over 3,000 Oncologists and Good Research Practice (GRP platform) which includes comprehensive RNAi library, tools including genetic typing, bioinformatic analysis, genetic manipulation, as well as SOP and project management systems.
![]()
个人中心
我是园区
退出
